Anemia: Symptoms, Causes & Treatment – Cleveland Clinic

How do I take care of myself?

While some types of anemia are short-term and mild, others can last a lifetime. Regardless, there are several things you can do to help manage symptoms. Here are some suggestions:

If you have anemia, you should check with your provider if your symptoms get worse despite treatment or if you notice changes in your body that may be new symptoms.

Anemia may increase your risk of a heart attack. Call 911 if you have the following symptoms:

Anemia may affect your body in many ways. It may happen for many different reasons. If you have anemia, here are some questions you may want to ask your healthcare provider:

A note from Cleveland Clinic

Anemia happens when you dont have enough red blood cells or your red blood cells arent working as well as they could. Some people are born with forms of anemia, but most people who have anemia develop the condition over time. Thats why its important to keep track of changes in your body. For example, we all have days when we feel worn out. But if youre feeling very tired for several days despite getting rest, consider talking to your healthcare provider.

Read more here:
Anemia: Symptoms, Causes & Treatment - Cleveland Clinic

Abu Dhabi Stem Cells Center partners with Red Crescent to enhance bone marrow transplant accessibility for patients – Abu Dhabi Media Office

Abu Dhabi Stem Cells Center (ADSCC) has partnered with Emirates Red Crescent (ERC) to enhance accessibility to bone marrow transplants for patients in need, providing them with treatment and support via the centres dedicated Abu Dhabi Bone Marrow Transplant (BMT) Programme.

Under the partnership, ADSCC will provide medical consultations to patients referred by the medical committee of ERC. In addition, both entities will join efforts in fundraising initiatives aimed at supporting and financing BMT procedures for underprivileged patients.

The partnership aims to provide these critical treatments to individuals affected by various blood cancers, blood disorders, and autoimmune diseases like multiple sclerosis, ensuring they receive the highest standard of care and support throughout their treatment process by Abu Dhabi Bone Marrow Transplant program (ADBMT) at ADSCC, which is accredited as a Centre of Excellence in Hematopoietic Stem Cell Transplantation by the Department of Health Abu Dhabi.

The agreement was signed by His Excellency Mohammed Al Fahim, Deputy Secretary General of Support Services Sector at ERC and Dr Maysoon Al Karam, Chief Medical Officer of ADSCC.

His Excellency Mohammed Al Fahim said: The agreement with Abu Dhabi Stem Cells Center embodies the vision of the UAE Red Crescent of enhancing humanitarian partnerships with various local sectors, particularly the healthcare sector, which is currently a priority in the authority's local and international efforts. It reflects the shared goal between both parties of alleviating the suffering of patients, supporting their health needs, and strengthening cooperation to achieve better health outcomes for the Red Crescent's beneficiaries. I would like to express our appreciation for such initiatives that address the health needs of vulnerable groups and commend Abu Dhabi Stem Cell Center's (ADSCC) efforts, and their contributions to advancing treatment and healing. The alignment of visions between the UAE Red Crescent and ADSCC, highlights the importance and potential for strategic partnerships in healthcare.

Dr Maysoon Al Karam said: "The UAEs leadership has always placed the health and wellbeing of its people at the forefront of its priorities, ensuring that high-quality healthcare services are accessible to all. This commitment underscores the essence of our collaboration with the Emirates Red Crescent, reflecting our joint vision to expand the accessibility of advanced medical treatments. Through such collaborations, we aim to bridge the gap in healthcare access, ensuring that state-of-the-art treatments are accessible to those in need. As a Centre of Excellence in Hematopoietic Stem Cell Transplantation, our Abu Dhabi Bone Marrow Transplant Programme has been offering holistic care for autologous and allogenic bone marrow transplant for adults and children since 2020. By providing advanced treatments locally, we eliminate the need for patients to seek medical care abroad. This not only enhances convenience for patients and their families but also plays a vital role in reducing the nation's healthcare expenditures.

To ensure healthcare access in the UAE, ADSCC is dedicated to collaborating with key stakeholders across the nation. This commitment is geared towards achieving our vision of pioneering innovative solutions to discover cures for diseases.

Visit link:
Abu Dhabi Stem Cells Center partners with Red Crescent to enhance bone marrow transplant accessibility for patients - Abu Dhabi Media Office

ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it has again successfully defended against opposition filed against a key patent for its ADAR-mediated RNA editing platform Axiomer™.

See the rest here:
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio

Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology…

- Intranasal foralumab attenuated microglial activation in patients with non-active secondary progressive multiple sclerosis and progression independent of relapse (PIRA) -- Data presented in a platform session at the Annual Meeting of the American Academy of Neurology in Denver, Colorado -

See original here:
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology...

Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene…

MALVERN, Pa., April 19, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that dosing is complete in the second cohort of its Phase 1/2 ArMaDa clinical trial for OCU410 (AAV-hRORA)—a modifier gene therapy candidate being developed for geographic atrophy (GA), an advanced stage of dry age-related macular degeneration (dAMD). GA affects approximately 1 million people in the United States alone.

See original here:
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene...

3Daughters Named “Startup of the Year” at BioLabs Philadelphia Investor Day 2024

MANSFIELD, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- 3Daughters, Inc., a clinical development company fueling evolutionary healthcare for women, was voted the “Startup of Year” by top life science investors and venture capitalists at the 2024 BioLabs Investor Day that took place in Philadelphia on April 16, 2024.

Read more from the original source:
3Daughters Named “Startup of the Year” at BioLabs Philadelphia Investor Day 2024

CorMedix Inc. Announces CMS Grants TDAPA to DefenCath

BERKELEY HEIGHTS, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that the Center for Medicare & Medicaid Services (CMS) has determined that DefenCath® meets the criteria for a Transitional Drug Add-On Payment (TDAPA) in the anti-infective functional category, beginning on July 1, 2024. The TDAPA program currently provides for five years of additional payment reimbursement beyond the ESRD bundled rate to outpatient providers, and aligns with CorMedix’s upcoming outpatient launch in July.

Read the rest here:
CorMedix Inc. Announces CMS Grants TDAPA to DefenCath

PharmAla Closes Private Placement and Concurrent Debt Settlement

VANCOUVER, British Columbia, April 19, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that, further to its press release dated April 10, 2024 (the “April 10 Release”), the Company has closed its previously announced non-brokered private placement offering (the “Offering”) effective today (the “Closing Date”) through the issuance of 4,166,665 Units for gross proceed of $750,000. Capitalized terms not otherwise defined herein have the meanings attributed to them in the April 10 Release.

More here:
PharmAla Closes Private Placement and Concurrent Debt Settlement

TScan Therapeutics Announces Closing of Upsized Public Offering

WALTHAM, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the closing of an underwritten public offering of 2,472,581 shares of its voting common stock at a public offering price of $7.1300 per share, which was equal to the closing price of its voting common stock on the Nasdaq Global Market on April 16, 2024, and pre-funded warrants to purchase up to an aggregate of 18,577,419 shares of its voting common stock at a price to the public of $7.1299 per pre-funded warrant to purchase one share of the voting common stock, which represents the per share public offering price for the voting common stock less the $0.0001 per share exercise price for each such pre-funded warrant. In addition, TScan has granted the underwriters a 30-day option to purchase up to an additional 3,157,500 shares of its voting common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to TScan from this offering were approximately $150.1 million, prior to any exercise of the underwriters’ option to purchase additional shares of voting common stock and before deducting underwriting discounts and commissions and other estimated offering expenses payable by TScan.

See the original post here:
TScan Therapeutics Announces Closing of Upsized Public Offering